Travere Therapeutics
TVTX
NASDAQ
IPO2003
about TVTX
Travere Therapeutics specializes in developing innovative therapies for rare and severe autoimmune diseases, including a pipeline of biologic and oral treatments aimed at addressing significant unmet medical needs.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $23.01 | $26.00 | $22.80 | $3.1B | 8.76M |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| +$0.29 | n/a | 14.37 | 15.12% | 15.59% | 0% |